Zobrazeno 1 - 10 of 34 pro vyhledávání: '"X Charlene Liao"'
7
Blocking LAIR1 signaling in immune cells inhibits tumor development
Autor: Jingjing Xie, Xun Gui, Mi Deng, Heyu Chen, Yuanzhi Chen, Xiaoye Liu, Zhiqiang Ku, Lingxiao Tan, Ryan Huang, Yubo He, Bruce Zhang, Cheryl Lewis, Kenian Chen, Lin Xu, Jian Xu, Tao Huang, X. Charlene Liao, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang
Publikováno v: Frontiers in Immunology. 13
The current immune checkpoint blockade therapy has been successful in treating some cancers but not others. New molecular targets and therapeutic approaches of cancer immunology need to be identified. Leukocyte associated immunoglobulin like receptor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::176e1e6b10bb64afcd3c49007548e7e9
https://doi.org/10.3389/fimmu.2022.996026
Zobrazit plný text záznamu
8
Abstract LB217: A novel bispecific LILRB4/CD3 antibody with potent killing of monocytic acute myeloid leukemia cells
Autor: Tao Huang, Kyu Hong, Krista McCutcheon, Jing-Tyan Ma, Ying Zhu, Mi Deng, Cheng Cheng Zhang, Paul Woodard, Hong Xiang, Xiao Min Schebye, X. Charlene Liao
Publikováno v: Cancer Research. 83:LB217-LB217
Background: Acute myeloid leukemia (AML) remains one of the highest unmet needs among human cancers. LILRB4 is specifically expressed on M4 myelomonocytic and M5 monocytic AML cells with a lack of expression on normal hematopoietic stem cells and pro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::863b9270137f9cd252e504ce954ac70e
https://doi.org/10.1158/1538-7445.am2023-lb217
Zobrazit plný text záznamu
9
304 Antagonistic antibodies targeting LAIR1 enhance T lymphocyte activation and promote inflammatory phenotypes in myeloid cells
Autor: X. Charlene Liao, Azita Tabrizi, Jing-Tyan Ma, Heyu Chen, Caroline Bonnans, Krista McCutcheon, Cheng Cheng Zhang, Jingjing Xie, Ningyan Zhang, Zhiqiang An, An Song, Marco Costa, Hongyu Tian, Tao Huang, Xun Gui, Kyu Hong, Ryan Stafford
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe Leukocyte Associated Immunoglobulin-like Receptor 1 (LAIR1) is an immune inhibitory transmembrane glycoprotein expressed on lymphocytes and myeloid cells. The known ligands for LAIR1 are proteins containing collagen-like domains includi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99765f5ca74371e49013224e03da2304
https://doaj.org/article/32c0a8d9110944f2aca679ae4d4aa3f6
Zobrazit plný text záznamu
10
Abstract CT209: A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348)
Autor: John Powderly, Manish Patel, Paul Woodard, Luke Chung, Hongyu Tian, Elizabeth Wieland, Kyu Hong, Maria Jose Costa, X. Charlene Liao, Matthew Taylor
Publikováno v: Cancer Research. 82:CT209-CT209
Cancer immunotherapy has entered the mainstream with approval of T-cell checkpoint inhibitors. However, most patients with advanced solid tumors do not derive benefits, or relapse after T-cell checkpoint blockade. Myeloid checkpoint inhibition is a n
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25da70f7900d9a9b1e94a37b89465a04
https://doi.org/10.1158/1538-7445.am2022-ct209
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje